Late-day intraocular pressure–lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial

Table 2 Treatment-emergent adverse events (safety population)

	TRAV	BIM
	(n = 84)	(n = 84)
Total TEAEs, n*	5	5
Patients with ≥1 TEAE, n (%)	2 (2)	4 (5)
TEAEs, n (%)
Chalazion	1 (1)	0
Allergic conjunctivitis	0	1 (1)
Eye irritation	0	1 (1)
Vitreous floater	0	1 (1)
Bronchitis	1 (1)	0
Upper respiratory tract infection	0	1 (1)
Urinary tract infection	1 (1)	0
Fall	1 (1)	0
Panic attack	1 (1)	0
Face swelling	0	1 (1)

BIM = bimatoprost 0.01%; TEAE = treatment-emergent adverse event; TRAV = benzalkonium chloride–free travoprost 0.004%.
*Reflects all adverse events for all patients.

ISSN: 1471-2415